-
Areas
Technologies
  • Clinical trials
  • Cohort studies
  • Cohort analysis

About

There are five clear areas of focus for the translational research undertaken by the Gibbs Lab.

* We lead national and international cancer registries that capture comprehensive patient, tumour, treatment and outcome data for all major solid cancers. This data is used to enable audit and research, including supporting the novel concept of registry based clinical trials in oncology collection and translational research by combining data and tissue based research.

* More recently the Gibbs Lab have partnered with the Victorian Comprehensive Cancer Centre (VCCC) to undertake a number of registry-based trials. This work is ongoing with a number of new trial designs under review for inclusion as we expand the portfolio to different modalities of treatment of patients with cancer

* We lead multiple international randomised trials to define the potential of ctDNA as a marker of minimal residual disease to determine recurrence risk and to optimise adjuvant therapy.

* We have initiated studies of patient derived tumour organoids, with the ultimate aim of in vitro sensitivity testing being used to guide clinical treatment selection.

* Clinical Trials working with cooperative groups such as the AGITG and others to provide all aspects of clinical trial start up, initiation, study management to data analysis and close out.

Each program is led by a medical oncologist with appropriate sub-speciality expertise and substantial clinical appointments, with the ultimate focus being clinical relevance and impact.

Publications

Selected publications from Prof Peter Gibbs

Williams C, Inderjeeth A-J, Hong W, McKenzie J, Anton A, Weickhardt A, Wong S, Shapiro J, Parente P, Goh J, Torres J, Smith A, Joshua A, Brown S, Steer C, Johns J, Gibbs P, Tran B, Azad AA. Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study. Clinical Genitourinary Cancer. 2025;23(3):10.1016/j.clgc.2025.102345

Farbotko S, Owen A, Orchard SG, Woods RL, Nelson M, Stocks NP, Tonkin A, Wolfe R, McNeil J, Gibbs P, Zalcberg J, Ryan J. Incidence of major health events across metropolitan and regional areas: A 10+ year prospective study of 16,697 older Australians. Australasian Journal on Ageing. 2025;44(2):10.1111/ajag.70036

McLachlan S-A, Mostafa R, Sharpe L, Burge ME, Day F, Blum RH, Campbell R, Lynam JF, Lee B, Singh MS, Lee M, Chantrill LA, Lundy J, Wong ZW, Wong R, Joshi S, Saqib A, Karikios DJ, Gibbs P, Tie J. Circulating tumor DNA (ctDNA) analysis guiding adjuvant therapy in patients (pts) with colorectal cancer (CRC): Impact on fear of cancer recurrence (FCR).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.11125

Hecht JR, Elez E, Eng C, Gibbs P, Seligmann JF, Xu R-H, Yamaguchi K, Wang C-Y, Teng HW, Trani L, Wortman-Vayn H, Jiang Z, Diorio B, Lorenzini PA, Baudelet C, Sethi SN, Baig M, Cremolini C. OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.tps3638

Sanderson E, Gibbs P, Tie J. The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer. The Lancet Regional Health – Western Pacific. 2025;59:10.1016/j.lanwpc.2025.101595

Tie J, Wang Y, Loree JM, Cohen JD, Espinosa D, Wong R, Price TJ, Tebbutt NC, Lee M, Burge ME, Harris SJ, Lee B, Lynam JF, O’Callaghan CJ, Breadner DA, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).Journal of Clinical Oncology. 2025;43(16_suppl):10.1200/jco.2025.43.16_suppl.3503

Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R, Shapiro JD, Harris SJ, Khattak A, Burge ME, Lee M, Harris M, McLachlan S-A, Horvath L, Karapetis C, Shannon J, Singh M, Yip D, Ananda S, Underhill C, Ptak J, Silliman N, Dobbyn L, Popoli M, Papadopoulos N, Tomasetti C, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nature Medicine. 2025;31(5):10.1038/s41591-025-03579-w

Kim GY, Tie J, Gibbs P. Letter to the Editor: Are We Asking the Right Question for New Biomarkers – “Ready for Prime Time” Versus Demonstrated Clinical Utility?. Journal of the National Comprehensive Cancer Network. 2025;23(5):10.6004/jnccn.2025.7037

Gard G, Oakley J, Serena K, Harold M, Gray K, Anderson H, Byrne J, Cockwill J, Cormack J, Down G, Kiossoglou G, Gibbs P. Stronger together; evaluating consumers and researchers working in partnership. Research Involvement and Engagement. 2025;11(1):10.1186/s40900-025-00716-0

Besson A, Cao K, Mardinli A, Wirth L, Yeung J, Kokelaar R, Gibbs P, Reid F, Yeung JM. Artificial intelligence generated 3D body composition predicts dose modifications in patients undergoing neoadjuvant chemotherapy for rectal cancer. Journal of Cancer Research and Clinical Oncology. 2025;151(5):10.1007/s00432-025-06219-5

Lab research projects

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.